Molecular modeling of mu opioid receptor and receptor-ligand interaction. 1997

S B Rong, and Y C Zhu, and H L Jiang, and S R Zhao, and Q M Wang, and Z Q Chi, and K X Chen, and R Y Ji
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China. rong@iris3.shmm.ac.cn

OBJECTIVE To construct the 3D structural model of mu opioid receptor (mu OR) and study the interaction between mu OR and fentanyl derivatives. METHODS The 3D structure of mu OR was modeled using the bacteriorhodopsin (bRh) as a template, in which the alignments of transmembrane (TM) of bRh and mu OR were achieved by scoring the alignment between the amino acid sequence of mu OR and the structure of bRh. The fentanyl derivatives were docked into the 7 helices of mu OR and the binding energies were calculated. RESULTS (1) The receptor-ligand interaction models were obtained for fentanyl derivatives. (2) In these models, the fundamental binding sites were possibly Asp147 and His297. The negatively charged oxygen of Asp147 and the positively charged ammonium group of ligand formed the potent electrostatic and hydrogen-binding interactions. Whereas the interactions between the positively charged nitrogen of His297 and the carbonyl oxygen of ligand were weak. In addition, there were some pi-pi interactions between the receptor and the ligand. (3) The binding energies of the receptor-ligand complexes had a good correlation with the analgesic activities (-lg ED50) of the fentanyl derivatives. CONCLUSIONS This model is helpful for understanding the receptor-ligand interaction and for designing novel mu OR selective ligands.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005283 Fentanyl A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078) Phentanyl,Duragesic,Durogesic,Fentanest,Fentanyl Citrate,Fentora,R-4263,Sublimaze,Transmucosal Oral Fentanyl Citrate,R 4263,R4263
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D001436 Bacteriorhodopsins Rhodopsins found in the PURPLE MEMBRANE of halophilic archaea such as HALOBACTERIUM HALOBIUM. Bacteriorhodopsins function as an energy transducers, converting light energy into electrochemical energy via PROTON PUMPS. Bacteriorhodopsin
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D016415 Sequence Alignment The arrangement of two or more amino acid or base sequences from an organism or organisms in such a way as to align areas of the sequences sharing common properties. The degree of relatedness or homology between the sequences is predicted computationally or statistically based on weights assigned to the elements aligned between the sequences. This in turn can serve as a potential indicator of the genetic relatedness between the organisms. Sequence Homology Determination,Determination, Sequence Homology,Alignment, Sequence,Alignments, Sequence,Determinations, Sequence Homology,Sequence Alignments,Sequence Homology Determinations
D017450 Receptors, Opioid, mu A class of opioid receptors recognized by its pharmacological profile. Mu opioid receptors bind, in decreasing order of affinity, endorphins, dynorphins, met-enkephalin, and leu-enkephalin. They have also been shown to be molecular receptors for morphine. Morphine Receptors,Opioid Receptors, mu,Receptors, Morphine,Receptors, mu,Receptors, mu Opioid,mu Receptors,Morphine Receptor,mu Opioid Receptor,mu Receptor,Opioid Receptor, mu,Receptor, Morphine,Receptor, mu,Receptor, mu Opioid,mu Opioid Receptors

Related Publications

S B Rong, and Y C Zhu, and H L Jiang, and S R Zhao, and Q M Wang, and Z Q Chi, and K X Chen, and R Y Ji
March 1996, Zhongguo yao li xue bao = Acta pharmacologica Sinica,
S B Rong, and Y C Zhu, and H L Jiang, and S R Zhao, and Q M Wang, and Z Q Chi, and K X Chen, and R Y Ji
July 1999, Journal of computer-aided molecular design,
S B Rong, and Y C Zhu, and H L Jiang, and S R Zhao, and Q M Wang, and Z Q Chi, and K X Chen, and R Y Ji
December 1996, Bioorganic & medicinal chemistry,
S B Rong, and Y C Zhu, and H L Jiang, and S R Zhao, and Q M Wang, and Z Q Chi, and K X Chen, and R Y Ji
January 2002, Progress in medicinal chemistry,
S B Rong, and Y C Zhu, and H L Jiang, and S R Zhao, and Q M Wang, and Z Q Chi, and K X Chen, and R Y Ji
June 1987, General physiology and biophysics,
S B Rong, and Y C Zhu, and H L Jiang, and S R Zhao, and Q M Wang, and Z Q Chi, and K X Chen, and R Y Ji
February 2013, European journal of pharmacology,
S B Rong, and Y C Zhu, and H L Jiang, and S R Zhao, and Q M Wang, and Z Q Chi, and K X Chen, and R Y Ji
November 1997, The Journal of biological chemistry,
S B Rong, and Y C Zhu, and H L Jiang, and S R Zhao, and Q M Wang, and Z Q Chi, and K X Chen, and R Y Ji
January 2023, Frontiers in pharmacology,
S B Rong, and Y C Zhu, and H L Jiang, and S R Zhao, and Q M Wang, and Z Q Chi, and K X Chen, and R Y Ji
November 2022, Cell,
S B Rong, and Y C Zhu, and H L Jiang, and S R Zhao, and Q M Wang, and Z Q Chi, and K X Chen, and R Y Ji
December 2014, Biochemical pharmacology,
Copied contents to your clipboard!